SILOSilo Pharma, Inc.

Nasdaq silopharma.com


$ 1.68 $ 0.09 (5.36 %)    

Friday, 10-May-2024 14:10:28 EDT
QQQ $ 442.84 $ 1.02 (0.23 %)
DIA $ 394.52 $ -0.72 (-0.18 %)
SPY $ 520.61 $ 0.07 (0.01 %)
TLT $ 90.36 $ 0.23 (0.26 %)
GLD $ 216.28 $ -2.45 (-1.12 %)
$ 1.77
$ 1.68
$ 0.00 x 0
$ 0.00 x 0
$ 1.68 - $ 1.68
$ 1.22 - $ 3.05
3,656
na
4.96M
$ -13.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-25-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-24-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-01-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-29-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-14-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-20-2020 12-31-2019 10-K
19 11-13-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 04-04-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-13-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-02-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-17-2017 03-31-2017 10-Q
30 03-31-2017 12-31-2016 10-K
31 10-28-2016 09-30-2016 10-Q
32 09-30-2016 06-30-2016 10-Q
33 08-31-2016 03-31-2016 10-Q
34 06-14-2016 12-31-2015 10-K
35 11-20-2015 09-30-2015 10-Q
36 08-14-2015 06-30-2015 10-Q
37 05-15-2015 03-31-2015 10-Q
38 03-31-2015 12-31-2014 10-K
39 11-14-2014 09-30-2014 10-Q
40 08-12-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 silo-pharma-announces-results-for-intranasal-ptsd-treatment

Silo Pharma, Inc. (NASDAQ: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company foc...

 silo-pharma-set-to-acquire-exclusive-licensing-for-promising-alzheimers-disease-therapeutic-spc-14-shows-cognitive-and-stress-reduction-benefits-in-preclinical-models

SPC-14 shows cognitive and stress reduction benefits in preclinical models SARASOTA, FL, April 10, 2024 (GLOBE NEWSWIRE) --  Si...

 citizens-and-2-other-stocks-under-3-insiders-are-buying

The Dow Jones index closed lower by around 10 points on Monday. When insiders purchase or sell shares, it indicates their confi...

 silo-pharma-approved-extension-of-previously-announced-stock-repurchase-program-authorizing-purchase-of-up-to-1m-common-stock-until-april-30

- SEC Filing

 silo-pharma-and-3-other-stocks-under-5-insiders-are-buying

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confid...

 silo-pharma-exercises-option-for-exclusive-license-agreement-for-first-in-class-ptsd-and-stress-induced-anxiety-therapeutic

Exclusive license for development, manufacturing, and commercialization in process

 silo-pharma-files-patent-for-groundbreaking-ketamine-implant-therapeutic-to-target-fibromyalgia-and-chronic-pain

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focu...

Core News & Articles

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

 silo-pharmas-provides-update-on-sp-26

Initial indications target fibromyalgia and chronic painLoaded and encapsulated drug maintains structural stability as implanta...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION